Cancers Treated:
Specializing In:
- Brain metastases of breast cancer
- Metastatic breast cancer
Research Interests:
- Quiescent cancer cells
- Drug resistance
- Metastatic breast cancer
- Dormancy
- Biomarkers
Positions
Roswell Park Comprehensive Cancer Center
- Associate Professor of Oncology
- Chief of Breast Medicine – Department of Medicine
- Director of Breast Translational Research
- Department of Molecular and Cellular Biology
Background
Education and Training
- 2009 - BMBCH - Oxford University Medical School, Oxford, England
- 2006 - MA - University of Cambridge, Cambridge, England
- 2004 - BS - Yale College, New Haven, CT
Residency
- 2010-2013 - Mass General Hospital, Boston, MA
Fellowship
- 2013-2017 - Dana-Farber Cancer Institute and Mass General Brigham, Boston, MA
Board Certification
- Internal Medicine - American Board of Internal Medicine
- Medical Oncology - American Board of Medical Specialties
Professional Memberships
- AACR
- ASCO
- American Society of Cell Biology
Research Overview
Clinical Trials
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
Learn More
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Learn More
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
Learn More
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Learn More